spacer
home > epc > spring 2017 > risky business
PUBLICATIONS
European Pharmaceutical Contractor

Risky Business

The globalisation of clinical trials and speciality pharmaceutical commercialisation, along with the rise of complex biologicalbased drug therapies, presents a host of opportunities for manufacturers. However, today’s mobile supply chain also comes with substantial risks. If overlooked, it can leave manufacturers, investors and an industry worth approximately $1.1 trillion exposed to potentially significant losses.

Managing the transportation of biopharmaceutical logistics cost almost $79 billion in 2016, with temperature-controlled products accounting for nearly $13 billion, according to Pharmaceutical Commerce’s annual Biopharma Cold Chain Sourcebook. With a growth rate of 8-9% year-on-year, spending on temperature-controlled logistics is predicted to rise to almost $17 billion by 2020, and the non-cold chain is estimated at $77 billion.

Such expense necessitates the identification and qualification of investment to mitigate mounting risks.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Nils Markmann is Vice President of Global Operations at World Courier and is responsible for the daily management of their global operation in terms of networkwide implementation and adherence to global standards, as well as for ensuring consistent operational excellence throughout the company’s 140 offices. Formerly General Manager of Operations for World Courier Germany, Nils has been with the company since 1995.
spacer
Nils Markmann
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

When space is tight

Existing packaging lines can be retrofitted for serialization tasks, achieving a maximum of space savings and process reliability: if required, the system comes with an integrated checkweigher and tamper-evident labeler.  
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

14th Annual Biomarkers & Immuno-Oncology World Congress

11-13 June 2018, Westin Boston Waterfront, Boston, Massachusetts

The Biomarkers and Immuno-Oncology World Congress brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement